Study on the Potential of Snail Seromucous and Chitosan as an Alternative Anti-Tuberculosis Drugs

This study highlights the sensitivity of Mycobacterium tuberculosis isolates from suspect tuberculosis patients to seromucous of snail and chitosan as an alternative to anti-tuberculosis drugs.

This research is based on the results of laboratory experiments.

The research stages include management specimen, freeze-drying of snail seromucous; formulation of dosage preparation; identification of MTB isolates; and drug susceptibility testing (DST) of MTB isolates to snail seromucous, chitosan, and ATD (streptomycin, isoniazid, rifampicin, and ethambutol). M. tuberculosis isolates used in the study was obtained from the results of the screening of sputum samples of suspect tuberculosis patients through microscopic smear examination and molecular rapid test (MRT) using Genexpert tools. M. tuberculosis isolates in patients who suspect tuberculosis are resistant against seromucous of snails and chitosan, that it is compared with SIRE. The dosage of snail seromucous is 8,000 mg/l, chitosan 2% is 800 mg/l, and streptomycin 800 mg/l, isoniazid 20 mg/l, rifampicin 8000 mg/l, ethambutol 200mg/l (SIRE). Data were analyzed using percentage of resistance of M. tuberculosis isolates against seromucous of snail, chitosan, and ATD.

The results showed that M. tuberculosis isolates in patients who suspect tuberculosis are resistant against seromucous of the snails, and chitosan, that it is compared with SIRE.

The effectiveness of a bactericidal or bacteriostatic drug against M. tuberculosis isolates can be influenced by the physiological bacterial cells as genetic factors related to the level of resistance or cell virulence and mutation process caused by mutagenic agents in physical chemistry from environmental factors. Therefore it is necessary to conduct further research related to the greater number of samples and the formulation of test preparations in combination with ATD.